CASI Pharmaceuticals, Inc. (NASDAQ:CASI) is set to issue its quarterly earnings data on Monday, November 13th.
CASI Pharmaceuticals (NASDAQ:CASI) last announced its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.01). On average, analysts expect CASI Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
CASI Pharmaceuticals, Inc. (NASDAQ CASI) opened at $2.40 on Friday. CASI Pharmaceuticals, Inc. has a 52 week low of $0.91 and a 52 week high of $4.84.
CASI has been the topic of several research analyst reports. ValuEngine cut CASI Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, July 22nd. Maxim Group set a $4.00 price objective on CASI Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, August 14th. Finally, HC Wainwright reissued a “buy” rating and issued a $2.00 price objective on shares of CASI Pharmaceuticals in a research note on Friday, September 8th.
In related news, Director Wei-Wu He bought 100,000 shares of the stock in a transaction on Tuesday, October 10th. The stock was bought at an average price of $1.95 per share, for a total transaction of $195,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last 90 days, insiders have acquired 996,329 shares of company stock valued at $1,647,138. 13.01% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: This story was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2017/11/12/casi-pharmaceuticals-inc-casi-set-to-announce-quarterly-earnings-on-monday.html.
CASI Pharmaceuticals Company Profile
CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.
Receive News & Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.